Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

FDA Requires Boxed Warning for Risk of T-Cell Malignancies With Approved CAR T-Cell Therapies

April 19th 2024

The FDA has mandated that the boxed warning for all approved CAR T-cell therapies be updated to include the serious risk of T-cell malignancies.

CLL/SLL Therapy Initiation at Specialty Pharmacies May Increase Treatment Adherence Rates

April 18th 2024

Patients with chronic lymphocytic leukemia who initiated therapy through an integrated health-system specialty pharmacy had high therapy adherence rates.

BTK Inhibitor Selection for CLL/SLL Is Evolving in Community Settings

April 15th 2024

A retrospective cohort study acalabrutinib and zanubrutinib are being increasingly adopted for the treatment of CLL/SLL in the community setting.

March Approval Madness: OncLive’s Roundup of FDA Decisions in Oncology

April 13th 2024

In case you missed it, these were the key regulatory decisions made by the FDA in March 2024.

Retrospective Study Shows Frontline Zanubrutinib Associated With Fewer Cardiac AEs vs Ibrutinib and Acalabrutinib in CLL/SLL

April 12th 2024

A real-world study showed zanubrutinib was linked with fewer cardiac adverse effects vs ibrutinib and acalabrutinib in chronic lymphocytic leukemia.

Dr Dholaria on the Use of Liso-Cel in Relapsed/Refractory CLL

April 10th 2024

Bhagirathbhai Dholaria, MBBS, discusses the benefits and limitations of liso-cel for patients with relapsed/refractory chronic lymphocytic leukemia.

Dr Brown on the Potential for Pirtobrutinib to Address Treatment Discontinuation in CLL

April 9th 2024

Jennifer R. Brown, MD, PhD, discusses how pirtobrutinib may address BTK inhibitor discontinuation in chronic lymphocytic leukemia.

Dr Kenderian on the Efficacy of Liso-Cel in R/R CLL/SLL

April 6th 2024

Saad J. Kenderian, MB, CHB, consultant, discusses the safety and efficacy findings derived from the phase 1/2 TRANSCEND CLL 004 study in CLL/SLL.

Dr Sotomayor on the Integration of BTK Inhibitors into the CLL Treatment Arsenal

March 29th 2024

Eduardo Sotomayor, MD, discusses the current arsenal of BTK inhibitors in chronic lymphocytic leukemia.

Dr Kenderian on Moving Liso-Cel to the First Line of CLL Treatment

March 28th 2024

Saad J. Kenderian, MB, CHB, discusses ongoing research taking place to potentially move liso-cel into earlier lines of therapy for patients with CLL.

A Groundbreaking First in CLL/SLL: Liso-Cel Makes its Mark as Only CAR T-Cell Therapy Approved

March 25th 2024

Saad J. Kenderian, MB, CHB, expands on the significance of liso-cel’s approval in chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dr Brown on the Implications of Genomic Data for Pirtobrutinib Use in CLL

March 25th 2024

Jennifer R. Brown, MD, PhD, discusses results from a genomic analysis of responses with pirtobrutinib in patients with chronic lymphocytic leukemia.

MRD-Directed Ibrutinib Plus Venetoclax Bests FCR in CLL

March 20th 2024

MRD-guided ibrutinib plus venetoclax displays PFS and OS benefits over fludarabine plus cyclophosphamide and rituximab in chronic lymphocytic leukemia.

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024

In case you missed it, read a recap of every episode of OncLive On Air recorded in February 2024.

Dr Kenderian on the FDA Approval of Liso-Cel in Relapsed/Refractory CLL/SLL

March 15th 2024

Saad J. Kenderian, MD, CHB, discusses the FDA approval of lisocabtagene maraleucel for chronic lymphocytic leukemia or small lymphocytic lymphoma.

FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory CLL or SLL

March 15th 2024

The FDA has granted accelerated approval to lisocabtagene maraleucel for the treatment of select patients with relapsed/refractory CLL or SLL.

Venetoclax Displays Durable Efficacy in Relapsed/Refractory CLL

March 14th 2024

Patients with relapsed/refractory chronic lymphocytic leukemia experienced long-lasting responses with venetoclax.

FDA Lifts Partial Clinical Hold on Trial Evaluating NX-2127 in R/R B-Cell Malignancies

March 11th 2024

The FDA has lifted a partial clinical hold on a phase 1 trial evaluating NX-2127 in relapsed/refractory B-cell malignancies

Dr Feldman on the Importance of the TRANSCEND CLL 004 Trial in CLL/SLL

March 4th 2024

Tatyana Feldman, MD, discusses the TRANSCEND CLL 004 trial in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dr Sekeres on the Impact of BTK Inhibitors on Approaches to CLL Management

March 4th 2024

Mikkael A. Sekeres, MD, discusses how the emergence of BTK inhibitors have shifted approaches to the management of chronic lymphocytic leukemia.